2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1951

The Incidence Rate of Giant Cell Arteritis in Slovenia
Abstract Number: 4

The Influence of Adipokines on the Interaction of Rheumatoid Arthritis Synovial Fibroblasts with Endothelial Cells
Abstract Number: 3262

The Influence of Immunosuppressive Therapy on Microangiopathy in Systemic Sclerosis As Measured with Nailfoldcapillaroscopy
Abstract Number: 2654

The Influence of Patient Reported Morning Stiffness on Patient Global Assessment in Rheumatoid Arthritis Patients Not Achieving ACR/EULAR Boolean Remission in a Large US Registry
Abstract Number: 2562

The Inhibition of Wnt/Beta-Catenin Signaling Pathway Via Paricalcitol and Pyrvinium Ameliorates Experimental Arthritis
Abstract Number: 2902

The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study
Abstract Number: 1

The Integrin Very Late Antigen-4 Plays a Key Role in the Recruitment of B Cells at the Inflammatory Foci
Abstract Number: 533

The Interferon Gene Signature in Early Rheumatoid Arthritis Demonstrates No Significant Association with Disease Activity
Abstract Number: 762

The Interferon Signature Correlates with Longitudinal Disease Severity in Systemic Lupus Erythematosus, but Adds Little to Conventional Prognostic Indicators
Abstract Number: 254

The Interleukin-1 Inhibitor Canakinumab for Familial Mediterranean Fever: Long-Term Beneficial Effect in a Cohort of 13 Patients
Abstract Number: 2447

The Juvenile Arthritis Disease Activity Score Remains the Disease Activity Marker of Choice for Adults with Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 3257

The Link Between DAS28 and the Short-Term Risk of Acute Coronary Syndrome in RA, and Its Driving Factors
Abstract Number: 2711

The Lung Microbiome in Rheumatoid Arthritis and Associated Local/Systemic Autoimmunity
Abstract Number: 768

The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Instrument Correlates Between Trained Clinical Investigators and Clinicians
Abstract Number: 2469

The Lymphocyte Repertoire in Juvenile Dermatomyositis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].